Press Release

MONTREAL, June 10th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for chronic hepatitis B and D patients, presented the final follow-up data from the REP 401 study assessing the impact of addition of REP 2139-Mg or REP 2165-Mg to an existing backbone therapy of TDF and pegylated interferon in participants with chronic HBeAg negative HBV infection at the 2019 Science of HBV Cure Meeting being held June 7th-8th, 2019 in Singapore.

The initial high rates of functional control and functional cure of HBV observed at 24 weeks of follow-up have persisted to the end of the scheduled 48 weeks of follow-up, with 83% of participants who completed therapy achieving functional control of their infection no longer requiring therapy under current guidelines. Moreover, 40% of participants further maintained functional cure, indicating the successful restoration of strong immunological control of their chronic HBV infection in the absence of therapy. Additionally, 91% of patients have maintained persistently normal liver function with overall reversal of liver inflammation and fibrosis, now normal (as assessed by liver stiffness) in 57% of participants.

Meta-analysis of all HBeAg negative patients in the previous REP 301 and the current REP 401 trials revealed that the extent of transaminase flare activity occurring when HBsAg was < 1 IU/mL predicted virologic outcomes; increased flare activity while HBsAg was < 1 IU/mL increased the likelihood of establishing functional control and functional cure.

Replicor’s presentation is now available on the company’s website at www.replicor.com/science/conference-presentations. For further information about the 2019 Science of HBV Cure Meeting: https://www.scienceofhbvcure.com/.

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

Media Contact:
Natacha Dorget
ndorget@replicor.com
(514) 733-1998